Article
Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.
Virology journal - 6 Jun 2015
Aissa Larousse Jameleddine, Trimoulet Pascale, Recordon Pinson Patricia, Tauzin Brigitte, Azzouz Mohamed Mssadak, Ben Mami Nabyl, Cheikh Imed, Triki Henda, Fleury Hervé
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to inhibit NS5A activities and have been approved for the treatment of HCV infection. However the drawback of these direct acting antivirals (DAAs) is the emergence of resistance mutations. The prevalence of such mutations conferring resistance to HCV-NS5A inhibitors before treatment has not been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.